Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues. 2007

Michael Mullins, and Laurent Perreard, and John F Quackenbush, and Nicholas Gauthier, and Steven Bayer, and Matthew Ellis, and Joel Parker, and Charles M Perou, and Aniko Szabo, and Philip S Bernard
Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA.

BACKGROUND Microarray studies have identified different molecular subtypes of breast cancer with prognostic significance. To transition these classifications into the clinical laboratory, we have developed a real-time quantitative reverse transcription (qRT)-PCR assay to diagnose the biological subtypes of breast cancer from fresh-frozen (FF) and formalin-fixed, paraffin-embedded (FFPE) tissues. METHODS We used microarray data from 124 breast samples as a training set for classifying tumors into 4 previously defined molecular subtypes: Luminal, HER2(+)/ER(-), basal-like, and normal-like. We used the training set data in 2 different centroid-based algorithms to predict sample class on 35 breast tumors (test set) procured as FF and FFPE tissues (70 samples). We classified samples on the basis of large and minimized gene sets. We used the minimized gene set in a real-time qRT-PCR assay to predict sample subtype from the FF and FFPE tissues. We evaluated primer set performance between procurement methods by use of several measures of agreement. RESULTS The centroid-based algorithms were in complete agreement in classification from FFPE tissues by use of qRT-PCR and the minimized "intrinsic" gene set (40 classifiers). There was 94% (33 of 35) concordance between the diagnostic algorithms when comparing subtype classification from FF tissue by use of microarray (large and minimized gene set) and qRT-PCR data. We found that the ratio of the diagonal SD to the dynamic range was the best method for assessing agreement on a gene-by-gene basis. CONCLUSIONS Centroid-based algorithms are robust classifiers for breast cancer subtype assignment across platforms and procurement conditions.

UI MeSH Term Description Entries
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D005404 Fixatives Agents employed in the preparation of histologic or pathologic specimens for the purpose of maintaining the existing form and structure of all of the constituent elements. Great numbers of different agents are used; some are also decalcifying and hardening agents. They must quickly kill and coagulate living tissue. Fixative,Pickling Agents,Agents, Pickling
D005557 Formaldehyde A highly reactive aldehyde gas formed by oxidation or incomplete combustion of hydrocarbons. In solution, it has a wide range of uses: in the manufacture of resins and textiles, as a disinfectant, and as a laboratory fixative or preservative. Formaldehyde solution (formalin) is considered a hazardous compound, and its vapor toxic. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p717) Formalin,Formol,Methanal,Oxomethane
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000465 Algorithms A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task. Algorithm
D013048 Specimen Handling Procedures for collecting, preserving, and transporting of specimens sufficiently stable to provide accurate and precise results suitable for clinical interpretation. Specimen Collection,Collection, Specimen,Collections, Specimen,Handling, Specimen,Handlings, Specimen,Specimen Collections,Specimen Handlings
D015925 Cryopreservation Preservation of cells, tissues, organs, or embryos by freezing. In histological preparations, cryopreservation or cryofixation is used to maintain the existing form, structure, and chemical composition of all the constituent elements of the specimens. Cryofixation,Cryonic Suspension,Cryonic Suspensions,Suspension, Cryonic
D016612 Paraffin Embedding The infiltrating of tissue specimens with paraffin, as a supporting substance, to prepare for sectioning with a microtome. Embedding, Paraffin

Related Publications

Michael Mullins, and Laurent Perreard, and John F Quackenbush, and Nicholas Gauthier, and Steven Bayer, and Matthew Ellis, and Joel Parker, and Charles M Perou, and Aniko Szabo, and Philip S Bernard
May 2010, BioTechniques,
Michael Mullins, and Laurent Perreard, and John F Quackenbush, and Nicholas Gauthier, and Steven Bayer, and Matthew Ellis, and Joel Parker, and Charles M Perou, and Aniko Szabo, and Philip S Bernard
January 2011, Urologic oncology,
Michael Mullins, and Laurent Perreard, and John F Quackenbush, and Nicholas Gauthier, and Steven Bayer, and Matthew Ellis, and Joel Parker, and Charles M Perou, and Aniko Szabo, and Philip S Bernard
February 2003, Journal of clinical microbiology,
Michael Mullins, and Laurent Perreard, and John F Quackenbush, and Nicholas Gauthier, and Steven Bayer, and Matthew Ellis, and Joel Parker, and Charles M Perou, and Aniko Szabo, and Philip S Bernard
May 2009, BMC medical genomics,
Michael Mullins, and Laurent Perreard, and John F Quackenbush, and Nicholas Gauthier, and Steven Bayer, and Matthew Ellis, and Joel Parker, and Charles M Perou, and Aniko Szabo, and Philip S Bernard
January 2024, PloS one,
Michael Mullins, and Laurent Perreard, and John F Quackenbush, and Nicholas Gauthier, and Steven Bayer, and Matthew Ellis, and Joel Parker, and Charles M Perou, and Aniko Szabo, and Philip S Bernard
January 2014, International journal of clinical and experimental pathology,
Michael Mullins, and Laurent Perreard, and John F Quackenbush, and Nicholas Gauthier, and Steven Bayer, and Matthew Ellis, and Joel Parker, and Charles M Perou, and Aniko Szabo, and Philip S Bernard
January 2013, PloS one,
Michael Mullins, and Laurent Perreard, and John F Quackenbush, and Nicholas Gauthier, and Steven Bayer, and Matthew Ellis, and Joel Parker, and Charles M Perou, and Aniko Szabo, and Philip S Bernard
October 2021, Cancers,
Michael Mullins, and Laurent Perreard, and John F Quackenbush, and Nicholas Gauthier, and Steven Bayer, and Matthew Ellis, and Joel Parker, and Charles M Perou, and Aniko Szabo, and Philip S Bernard
May 2000, The Journal of molecular diagnostics : JMD,
Michael Mullins, and Laurent Perreard, and John F Quackenbush, and Nicholas Gauthier, and Steven Bayer, and Matthew Ellis, and Joel Parker, and Charles M Perou, and Aniko Szabo, and Philip S Bernard
May 2020, International journal of legal medicine,
Copied contents to your clipboard!